Biomarkers and Right Ventricular Dysfunction - 13/11/19

Doi : 10.1016/j.ccc.2019.08.011

Natasha M. Pradhan, MBBS ^a, Christopher Mullin, MD, MHS ^b, Hooman D. Poor, MD ^a,^⁎
^a Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai Hospital, 1 Gustave L. Levy Place, New York, NY 10029-5674, USA
^b Division of Pulmonary, Critical Care, and Sleep Medicine, Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA

^∗Correspondence: Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai Hospital, 1 Gustave L. Levy Place, New York, NY 10029-5674.Division of Pulmonary, Critical Care, and Sleep MedicineIcahn School of Medicine at Mount Sinai Hospital1 Gustave L. Levy PlaceNew YorkNY10029-5674

Résumé

Right ventricular failure is common in critically ill patients, as it frequently results from pulmonary embolism or pulmonary hypertension, and can complicate sepsis and the acute respiratory distress syndrome. Right ventricular dysfunction can be challenging to manage and is associated with poor outcomes in this wide array of disease. Laboratory biomarkers are rapid, noninvasive, accurate, and widely available and thus are useful in the diagnosis and management of right ventricular dysfunction in the critically ill patient. This article discusses the pathophysiology of right ventricular failure and reviews the applications of commonly used biomarkers in right ventricular dysfunction in critical care.

Le texte complet de cet article est disponible en PDF.

Keywords : Right ventricular dysfunction, Biomarkers, Pulmonary embolism, Pulmonary hypertension, Troponin, Brain natriuretic peptide